Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: J Neuroimmune Pharmacol. 2014 Aug 8;9(5):679–689. doi: 10.1007/s11481-014-9560-2

Fig 5.

Fig 5

IFNγ neutralizing antibody administration following MCAO decreases infarct volume. Administration of an IFNγ at 24, 48, and 72 h post-MCAO (n=3) significantly decreased infarct volume, as measured by Fluoro-Jade staining, at 96 h when compared to the vehicle (n=4) and isotype (n=5) control groups (*p<0.007; d). Representative micrographs of Fluoro-Jade stained brains from PBS vehicle (a), IgG isotype (b), and IFNγ antibody (c) treatment groups 96 h post-MCAO. Scale bars = 2 mm.